Literature DB >> 16480398

The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy.

S J O Veldhuyzen van Zanten1, A B R Thomson, A N Barkun, D Armstrong, N Chiba, R J White, S Escobedo, P Sinclair.   

Abstract

BACKGROUND: The prevalence of Barrett's oesophagus in patients undergoing gastroscopy may be influenced by possible referral bias. AIM: To present the prevalence of Barrett's oesophagus from the the Canadian Adult Dyspepsia Empirical Therapy Prompt Endoscopy study and to explore potential risk factors for its presence.
METHODS: Patients had not been on treatment for dyspepsia for 2-4 weeks prior to endoscopy, which was performed within 10 working days of presentation.
RESULTS: Barrett's oesophagus was endoscopically suspected in 53 of 1040 cases (5%) and histologically confirmed by the presence of intestinal metaplasia in 25 (2.4%). The prevalence of biopsy-proven Barrett's oesophagus was 4% in patients with dominant reflux-like symptoms. Sixty-four percent with confirmed Barrett's oesophagus had dominant reflux-like symptoms compared with 37% without Barrett's oesophagus. Barrett's oesophagus was more common in patients >50 years of age; 68% of cases were males. The mean duration of symptoms was 10 years, yet 16% had symptoms of <1-year duration. Endoscopic reflux oesophagitis was present in 68% of confirmed Barrett's oesophagus patients.
CONCLUSIONS: Barrett's oesophagus is confirmed on biopsy in about half of endoscopically suspected Barrett's oesophagus patients. Barrett's oesophagus is more common in males, in those with dominant reflux-like symptoms, and in patients with a longer symptom history.

Entities:  

Mesh:

Year:  2006        PMID: 16480398     DOI: 10.1111/j.1365-2036.2006.02813.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Screening and surveillance of Barrett's esophagus.

Authors:  Jeff Michalak; Ajay Bansal; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2009-06

2.  The global prevalence of Barrett's esophagus: A systematic review of the published literature.

Authors:  Inês Marques de Sá; Pedro Marcos; Prateek Sharma; Mário Dinis-Ribeiro
Journal:  United European Gastroenterol J       Date:  2020-07-06       Impact factor: 4.623

Review 3.  Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus.

Authors:  Justin B Taylor; Joel H Rubenstein
Journal:  Am J Gastroenterol       Date:  2010-05-18       Impact factor: 10.864

4.  Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Authors:  Reem Z Sharaiha; Daniel E Freedberg; Julian A Abrams; Y Claire Wang
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

Review 5.  Barrett's esophagus: a review of the literature.

Authors:  Erin W Gilbert; Renato A Luna; Vincent L Harrison; John G Hunter
Journal:  J Gastrointest Surg       Date:  2011-04-02       Impact factor: 3.452

6.  Prevalence of Barrett's esophagus in patients with moderate to severe erosive esophagitis.

Authors:  Nooman Gilani; Richard-D Gerkin; Francisco-C Ramirez; Shahina Hakim; Adam-C Randolph
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

7.  Barrett esophagus: perspectives on its diagnosis and management in asian populations.

Authors:  Yuji Amano; Yoshikazu Kinoshita
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

Review 8.  Helicobacter pylori infection reduces the risk of Barrett's esophagus: A meta-analysis and systematic review.

Authors:  Bálint Erőss; Nelli Farkas; Áron Vincze; Benedek Tinusz; László Szapáry; András Garami; Márta Balaskó; Patrícia Sarlós; László Czopf; Hussain Alizadeh; Zoltán Rakonczay; Tamás Habon; Péter Hegyi
Journal:  Helicobacter       Date:  2018-06-25       Impact factor: 5.753

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.